Clinical Efficacy of Pyrotinib Combined with Capecitabine in the Second-Line or Above Treatment for HER-2 Positive Advanced Breast Cancer and Its Association with Cell-Free DNA

PURPOSE: To evaluate the clinical efficacy of pyrotinib combined with capecitabine in the treatment of HER-2 positive breast cancer in real world and its correlation with cfDNA. METHODS: From September 2020 to June 2021, 181 cases of HER-2 positive advanced breast cancer patients who were treated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Yajun, Chen, Juan, Deng, Rong, Liu, Yufei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568365/
https://www.ncbi.nlm.nih.gov/pubmed/36245977
http://dx.doi.org/10.1155/2022/9449489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568365/
https://www.ncbi.nlm.nih.gov/pubmed/36245977
http://dx.doi.org/10.1155/2022/9449489

Ejemplares similares